EZH2 and cancer: Small-molecule inhibitors of EZH2, including GSK126, EPZ-6438, and 3-deazaneplanocin A (DZNep), have been proposed for therapeutic development in cancer.16, 17, 18 We have previously reported in vitro experiments that show that DZNep can irreversibly suppress classic morphological and biochemical changes associated with HSC transdifferentiation.14